Paloma Partners’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
– Sell
-3,838
Closed -$213K – 1532
2022
Q1
$213K Sell
3,838
-1,124
-23% -$57.7K 0.01% 1357
2021
Q4
$278K Buy
+4,962
New +$269K ﹤0.01% 1443
2017
Q1
– Sell
-137,822
Closed -$2.47M – 2152
2016
Q4
$2.47M Buy
137,822
+124,948
+971% +$2.27M 0.02% 553
2016
Q3
$268K Sell
12,874
-4,156
-24% -$103K ﹤0.01% 1658
2016
Q2
$458K Sell
17,030
-4,604
-21% -$126K 0.01% 1576
2016
Q1
$587K Buy
21,634
+12,676
+142% +$340K 0.01% 1221
2015
Q4
$260K Sell
8,958
-1,326
-13% -$36.7K 0.01% 1408
2015
Q3
$279K Buy
+10,284
New +$291K 0.01% 1312

Other funds holding NVO

Paloma Partners's NVO Position: Q2 2022 in Review

Paloma Partners sold out of Novo Nordisk (NVO) in Q2 2022, closing a stake of 3,838 shares — an estimated $213K sold.

Paloma Partners first reported a position in NVO in Q3 2015 and held it in 8 quarters. The position peaked at $2.47M in Q4 2016. 932 funds tracked by Wall St. Rank hold NVO as of Q2 2022.

  • Paloma Partners reported no remaining Novo Nordisk position as of Q2 2022 after selling out during the quarter.
  • Paloma Partners sold 3,838 Novo Nordisk shares in Q2 2022, an estimated $213K.
  • Paloma Partners first reported a position in Novo Nordisk in Q3 2015 and held it in 8 quarters.
  • Paloma Partners's Novo Nordisk position peaked at $2.47M in Q4 2016.
  • 932 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2022.

Based on Paloma Partners's 13F filing for Q2 2022, filed 15 Aug 2022.